Enterococcus faecalis 20-SD-BW-08
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA179530 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Enterococcus faecalis 20-SD-BW-06 Genome sequencing and assembly
| PRJNA179539 | ENA
Project description:Enterococcus faecalis 02-MB-BW-10 Genome sequencing and assembly
| PRJNA179538 | ENA
Project description:Neisseria gonorrhoeae strain:20/22/08 Genome sequencing
| PRJNA1097266 | ENA
Project description:Enterococcus faecalis 13-SD-W-01 Genome sequencing and assembly
| PRJNA179531 | ENA
Project description:Enterococcus faecalis 20.SD.W.06 Genome sequencing and assembly
| PRJNA179390 | ENA
Project description:RNA-sequencing on human leukemia cell lines MOLM13 (AML, MLL-AF9+) and K562 (CML-BC, BCR-ABL+) after Ro 08-2750 treatment (20 uM, 4hours)
2019-05-09 | GSE114320 | GEO
Project description:The biofilm proteome profile of endodontic and systemic pathogen E. faecalis has been analysed in this study to identify markers associated with its biofilm formation. Strong and weak biofilm forming E. faecalis clinical isolates were compared with two standard ATCC strains of E. faecalis in order to elucidate the biological pathways associated with the biofilm formation capability of E. faecalis.
2018-01-29 | PXD006542 | Pride
Project description:Hepatic fibrosis is a dynamic process characterized by the net accumulation of extracellular matrix resulting from chronic liver injury such as nonalcoholic steatohepatitis. During the pathogenesis of hepatic fibrosis, activation of hepatic stellate cells (HSCs) causes transdifferentiation of quiescent cells into proliferative and fibrogenic myofibroblasts. In the present study, we developed a novel RORα-selective ligand, ODH-08, based on the modification of JC1-40, a previously reported N-methylthiourea analog. Administration of ODH-08 to Western diet (WD)-fed mice improved the signs of hepatic fibrosis: decreased hepatic collagen deposition and suppression of the expression of fibrogenic markers. ODH-08 inhibits the TGF1-induced fibrogenic activation of HSCs through suppression of the TGFβ1–SMAD signaling pathway, which represents a novel mechanism for the antifibrogenic effect of RORα. Thus, ODH-08 appears to be a promising antifibrotic agent to treat hepatic fibrosis. We performed a microarray analysis in the liver tissue of ODH-08-treated WD-fed mice to anlyse differentially expressed genes under ODH-08 administration. The control group was vehicle-treated WD-fed mice.
2024-03-01 | GSE250531 | GEO
Project description:Indian rhesus macaques are arguably the most reliable animal models in AIDS research. In this species the MHC class I allele Mamu-B*08, among others, is associated with elite control of SIV replication. A similar scenario is observed in humans where the expression of HLA-B*27 or HLA-B*57 has been linked to slow or no progression to AIDS after HIV infection. Despite having large differences in their primary structure, it has been reported that HLA-B*27 and Mamu-B*08 display peptides with sequence similarity. To fine-map the Mamu-B*08 binding motif and assess its similarities with that of HLA-B*27 we affinity purified the peptidomes bound to these MHC class I molecules and analyzed them by LC-MS/MS identifying several thousands of endogenous ligands. Sequence analysis of both sets of peptides revealed a degree of similarity in their binding motifs, especially at peptide position 2 (P2) where arginine was present in the vast majority of ligands of both allotypes. In addition, several differences emerged from this analysis: (i) ligands displayed by Mamu-B*08 tended to be shorter and to have lower molecular weight, (ii) Mamu-B*08 showed a higher preference for glutamine at P2 as a suboptimal binding motif and (iii) the second major anchor position, found at P-omega, was much more restrictive in Mamu-B*08. In this regard, HLA-B*27 bound efficiently peptides with aliphatic, aromatic (including tyrosine) and basic C-terminal residues while Mamu-B*08 preferred peptides with leucine and phenylalanine in this position. These results deepen our understanding of the molecular basis of the presentation of peptides by Mamu-B*08 and can contribute to the detection of novel SIV epitopes restricted by this allotype.
2016-10-07 | PXD004964 | Pride
Project description:Introduction Current research efforts attempt to increase therapy efficacy in diffuse large B-cell lymphoma (DLBCL). Here, we evaluated the effects of small molecule inhibitor Ro 08-2750 on therapy-induced cytotoxicity in DLBCL. Material and methods First, we established Ro 08-2750 treatment in DLBCL by verifying cell toxicity via cell viability and colony formation assays. In a next step, functional effects reducing cell viability, e.g. cell cycle dysregulation and apoptosis, were analyzed via flow cytometry. Then, we evaluated effects of Ro 08-2750 on cytotoxic therapy in cell viability and colony formation assays. After confirming an increase in irradiation-induced DNA damage via γH2AX assay, an immunoblot-based assay was used to detect changes in DNA damage response. Lastly, we analyzed Ro 08-2750-induced changes in gene and protein expression via RT-qPCR, RNA sequencing, western blot and proteomic analysis. Results Ro 08-2750 reduces cell viability dose-dependently in DLBCL. Functionally, the decrease in cell viability is combined with a cell cycle dysregulation, specifically an increase in S phase with reduced G2/M phase, and an increase in apoptosis. DNA synthesis is reduced during S phase. Assessing the therapeutical relevance, Ro 08-2750 sensitized DLBCL cell lines to irradiation but not chemotherapy and increased irradiation-induced double strand breaks. We found a dysregulation in CHK2 phosphorylation. Moreover, Ro 08-2750 dysregulated DNA damage response in genomic and proteomic analysis. Conclusion We identified Ro 08-2750 as a potential radiosensitizer in DLBCL. Therefore, our results indicate the potential therapeutical benefit of targeting RNA binding proteins
2026-07-03 | GSE301732 | GEO